{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.3","upperLimit":"64.7","value":"53.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"description":"The percentage of participants who achieved a CR or CRi at any time point during the study per the modified IWG criteria for AML and investigator assessment.\n\nCR: absolute neutrophil count (ANC) ≥ 10\\^3 /µL, platelet counts ≥ 10\\^5 /µL, red blood cell (RBC) transfusion independence (a period of at least 56 days with no RBC transfusion), and bone marrow with \\< 5% blasts.\n\nCRi: lack of morphologic evidence of leukemia (blasts \\< 5%), and platelet counts \\< 10\\^5 /µL or ANC \\< 10\\^3 /µL\n\nParticipants who never achieved CR or CRi or had no IWG disease assessment were considered to be non-responders in the calculation of CR + CRi rate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg, and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.\n\nParticipants could continue receiving treatment until disease progression or until discontinuation criteria were met.","id":"OG000","title":"Phase 1+2: 600 mg Venetoclax + LDAC"}],"paramType":"NUMBER","populationDescription":"All enrolled participants who received venetoclax with LDAC at the recommended Phase 2 dose (600 mg)","reportingStatus":"POSTED","timeFrame":"Response was assessed at Cycle 2, Day 1, Cycle 4, Day 1, and every 3 cycles thereafter; median duration of treatment was 4.2 months.","title":"Complete Remission Plus CR With Incomplete Blood Count Recovery (CRi) Rate","type":"SECONDARY","unitOfMeasure":"percentage of participants"}